Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

High treatment costs can restrict patient access to the most effective therapies, especially in low- and middle-income countries where healthcare costs are a significant burden. Regulatory Challenges: ...

Opens in a new tab or window Share on Bluesky ... "This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD," making SGLT2 and GLP-1 drugs preferable ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

The shares of Senores Pharmaceuticals Limited were trading at ₹570.70 up by ₹36.90 or 6.91% on the NSE today at 2.32 pm.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...